Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) have earned a consensus broker rating score of 1.75 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and two have issued a strong buy recommendation on the company.
Analysts have set a 1-year consensus price objective of $31.25 for the company and are anticipating that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also given Rhythm Pharmaceuticals an industry rank of 154 out of 265 based on the ratings given to related companies.
Several equities research analysts recently weighed in on RYTM shares. Morgan Stanley started coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued an “equal weight” rating and a $23.00 price target on the stock. Cowen started coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued an “outperform” rating and a $40.00 target price on the stock. BidaskClub cut Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Bank of America started coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 14th.
Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) traded up $0.45 during mid-day trading on Tuesday, reaching $27.40. The company had a trading volume of 31,892 shares, compared to its average volume of 164,575. The stock has a market capitalization of $747.59 and a PE ratio of -19.43. Rhythm Pharmaceuticals has a 12 month low of $21.38 and a 12 month high of $33.81.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($1.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($1.38). equities analysts anticipate that Rhythm Pharmaceuticals will post -1.63 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/04/zacks-rhythm-pharmaceuticals-inc-rytm-given-31-25-average-price-target-by-brokerages.html.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.